Quick Answer
Immunocore Holdings plc reported Diluted EPS of $0.71 per share (loss) for fiscal year 2025.
Immunocore Holdings plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.71 | +30.4% |
| 2024 | -$1.02 | +9.7% |
| 2023 | -$1.13 | +1.7% |
| 2022 | -$1.15 | +72.9% |
| 2021 | -$4.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | +100.0% |
| June 30, 2025 | -$0.20 | +13.0% | -300.0% |
| March 31, 2025 | $0.10 | +120.4% | -41.2% |
| September 30, 2024 | $0.17 | +750.0% | +173.9% |
| June 30, 2024 | -$0.23 | +34.3% | +53.1% |
| March 31, 2024 | -$0.49 | -22.5% | -2550.0% |
| September 30, 2023 | $0.02 | — | +105.7% |
| June 30, 2023 | -$0.35 | — | +12.5% |
- Immunocore Holdings plc showed an increase of +30.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Immunocore Holdings plc’s diluted eps has grown by 83.3% (from $4.24 per share (loss) to $0.71 per share (loss)).
- The most recent figure is from Immunocore Holdings plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: